“Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis” Alexandra M. Nanzer, Jaideep Dhariwal, Joanne Kavanagh, Andrew Hearn, Mariana Fernandes, Louise Thomson, Cris Roxas, Linda Green, Grainne D’Ancona, Sangita Agarwal, Brian D. Kent and David J. Jackson.
ERJ Open Res 2019; 6: 00272-2019

This article was originally published with an error in the vertical axis labels of figure 1c. The corrected caption is shown below, and the article has been corrected and republished online.

FIGURE 1 Reduction from baseline to 48 weeks in a) maintenance oral corticosteroid (mOCS) dose ($p=0.0018$), b) Birmingham Vasculitis Activity Score (BVAS) ($p=0.0007$) and c) Asthma Control Questionnaire score (ACQ) ($p=0.012$). Data are presented as a) median (interquartile range) and b and c) mean $\pm$ SD.

ERJ Open Res 2021; 7: 1 | DOI: 10.1183/23120541.50451-2020 | ©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org